With sales of vascular endothelial growth factor (VEGF) trap Eylea (aflibercept) as a monotherapy possibly slowing down, Regeneron Pharmaceuticals Inc. and Bayer AG have broadened their work in eye disease with a new $130 million agreement to test the treatment in combination with the angiopoietin2 (Ang2) antibody nesvacumab, and two phase II trials are enrolling patients with wet age-related macular degeneration (AMD) or diabetic macular edema (DME).